Trending Now
Royalty Pharma plc (RPRX): A Strategic Investment in Life-Changing Therapies
Royalty Pharma plc (Nasdaq: RPRX) closed December 27 at $25.54, up 0.55% for the day, with after-hours trading slightly declining to $25.50....
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Workhorse Group Inc (NASDAQ:WKHS) and Energous Corp (NASDAQ: WATT) up on...
Workhorse Group Inc (NASDAQ:WKHS) is setting up really nicely on a technical basis and has catalysts looming headed into 2020. This is...
MAKE IT MODERN
LATEST REVIEWS
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Demonstrates Improvement In Hemoglobin Using BCX9930 In...
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) showed improvement in hemoglobin and lowered transfusions using BCX9930, its oral D-factor, in PNH (paroxysmal nocturnal hemoglobinuria) patients in an...
MAKE IT MODERN
PERFORMANCE TRAINING
How the Oil Spike Could Spur a Stampede into Alternative Energy Solutions (CCJ, VKIN,...
One of the more interesting upshots of Russia’s invasion of Ukraine has been a big shift to the game theory landscape in...
Can Actinium Pharmaceuticals (ATNM) bounce back from the Regulatory Hurdles
In the realm of advanced cancer therapies, particularly for acute myeloid leukemia (AML), Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) stands out with...
The US FDA Grants Fast Track Designation To IND – LB1148 Of Palisade Bio...
The US FDA granted fast track designation to Palisade Bio Inc (NASDAQ:PALI)’s LB1148 to treat adhesions following pelvic or abdominal surgery.
Incyte (NASDAQ:INCY) Releases Phase 3 Jakafi® In Combination with SOC Study Results In Cytokine...
Incyte (NASDAQ:INCY) has released initial data from the phase 3 RUXCOVID study which showed that ruxolitinib (Jakafi®) combination with standard of care...
Intellia Therapeutics Inc. (NASDAQ:NTLA) Posts Collaboration Revenue Of $22.2 Million In Q3 2020 And...
Intellia Therapeutics Inc. (NASDAQ:NTLA) has announced results of the quarter ended September 30, 2020, in which its collaboration revenue was $22.2 million. The revenue...
MAKE IT MODERN
